COL-3-Induced Molecular and Ultrastructural Alterations in K562 Cells.

COL-3 K562 cells m-calpain paraptosis programmed necrosis

Journal

Journal of personalized medicine
ISSN: 2075-4426
Titre abrégé: J Pers Med
Pays: Switzerland
ID NLM: 101602269

Informations de publication

Date de publication:
04 Jan 2022
Historique:
received: 03 12 2021
revised: 28 12 2021
accepted: 30 12 2021
entrez: 21 1 2022
pubmed: 22 1 2022
medline: 22 1 2022
Statut: epublish

Résumé

Tetracycline-3 (4-dedimethylamino sancycline, COL-3) is a non-antibiotic tetracycline derivative. COL-3 exerts potent anti-metalloproteinase activity and its antitumor effects have been reported both in vitro and in vivo. In this study, we investigated the mechanisms of COL-3-induced cytotoxicity in a chronic myeloid leukemia cell line, K562, characterized by the BCR-ABL fusion protein. COL-3 induced K562 cell death in a concentration-dependent manner with an IC50 of 10.8 µg/mL and exhibited features of both apoptosis and necrosis. However, flow cytometry analysis revealed that necrotic cells dominated over the early and late apoptotic cells upon treatment with COL-3. Transmission electron microscopy analysis in combination with Western blotting (WB) analysis revealed early mitochondrial swelling accompanied by the early release of cytochrome c and truncated apoptosis inducing factor (tAIF). In addition, ultrastructural changes were detected in the endoplasmic reticulum (ER). COL-3 affected the levels of glucose-regulated protein-94 (GRP94) and resulted in m-calpain activation. DNA double strand breaks as a signature for DNA damage was also confirmed using an antibody against γH2AX. WB analyses did not demonstrate caspase activation, while Bcl-xL protein remained unaffected. In conclusion, COL-3-induced cell death involves DNA damage as well as mitochondrial and ER perturbation with features of paraptosis and programmed necrosis.

Identifiants

pubmed: 35055357
pii: jpm12010042
doi: 10.3390/jpm12010042
pmc: PMC8778770
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Karolinska Institute
ID : 20200788 (CiMED)
Organisme : Barncancerfonden
ID : PR2020-0151
Organisme : Swedish Cancer Society
ID : CAN2011/595
Organisme : Karolinska Institute
ID : 2018-02377
Organisme : Radium Hemmets Research Funds
ID : 161082

Références

J Cell Mol Med. 2010 Apr;14(4):970-81
pubmed: 20569277
Trends Mol Med. 2006 Sep;12(9):440-50
pubmed: 16899408
Cell Death Differ. 2012 Jan;19(1):107-20
pubmed: 21760595
Blood. 2014 Jun 19;123(25):3932-42
pubmed: 24825862
J Clin Oncol. 2006 Mar 20;24(9):1389-94
pubmed: 16549833
Nat Rev Cancer. 2020 Mar;20(3):158-173
pubmed: 31907378
Cell Death Differ. 2009 Jan;16(1):3-11
pubmed: 18846107
Int J Biol Macromol. 2003 Nov;33(1-3):49-56
pubmed: 14599584
Int J Cancer. 2002 Mar 10;98(2):297-309
pubmed: 11857423
FEBS J. 2019 Jan;286(2):241-278
pubmed: 30027602
Apoptosis. 2006 Sep;11(9):1463-71
pubmed: 16820960
Cell. 2011 Nov 11;147(4):742-58
pubmed: 22078876
Cancer Res. 1981 Jan;41(1):237-43
pubmed: 6934848
Science. 2002 Jul 12;297(5579):259-63
pubmed: 12114629
Nature. 1999 Jun 3;399(6735):483-7
pubmed: 10365962
Leukemia. 2002 Oct;16(10):2165-7
pubmed: 12357376
Biochimie. 2002 Feb-Mar;84(2-3):153-66
pubmed: 12022946
Cell Death Differ. 2005 Nov;12 Suppl 2:1478-80
pubmed: 16247494
J Pharm Sci. 1999 May;88(5):535-7
pubmed: 10229645
J Cell Biol. 2000 Sep 18;150(6):1489-98
pubmed: 10995452
Annu Rev Genet. 2009;43:95-118
pubmed: 19659442
Int J Cancer. 2006 Mar 1;118(5):1309-15
pubmed: 16152604
J Clin Oncol. 2002 Jan 1;20(1):153-9
pubmed: 11773164
PLoS One. 2014 Dec 15;9(12):e114457
pubmed: 25502932
Mol Cancer Ther. 2013 Oct;12(10):2078-87
pubmed: 23939379
Biochim Biophys Acta. 2009 Dec;1793(12):1848-59
pubmed: 19833151
Ann Clin Biochem. 2005 Nov;42(Pt 6):415-31
pubmed: 16259792
Leukemia. 2011 May;25(5):761-9
pubmed: 21350558
Adv Dent Res. 1998 Nov;12(2):5-11
pubmed: 9972116
FEBS Lett. 2000 Jul 7;476(3):118-23
pubmed: 10913597
Cell Chem Biol. 2018 Dec 20;25(12):1506-1518.e13
pubmed: 30318461
Science. 1975 Sep 12;189(4206):867
pubmed: 17812524
Cell Cycle. 2007 Nov 1;6(21):2612-9
pubmed: 17912035
Crit Rev Oncol Hematol. 2019 May;137:57-83
pubmed: 31014516
Leuk Res Treatment. 2012;2012:671702
pubmed: 23259070
FEBS J. 2015 Jan;282(1):19-31
pubmed: 25327580
Surg Neurol. 1985 Jul;24(1):67-72
pubmed: 4012564

Auteurs

Mona Fares (M)

Experimental Cancer Medicine, Division of Biomolecular and Cellular Medicine (BCM), Department of Laboratory Medicine, Novum, Karolinska Institutet, 141 57 Huddinge, Sweden.
Clinical Research Center and Center for Allogeneic Stem Cell Transplantation, Karolinska University Hospital, 141 86 Huddinge, Sweden.

Sandra Oerther (S)

Experimental Cancer Medicine, Division of Biomolecular and Cellular Medicine (BCM), Department of Laboratory Medicine, Novum, Karolinska Institutet, 141 57 Huddinge, Sweden.
Clinical Research Center and Center for Allogeneic Stem Cell Transplantation, Karolinska University Hospital, 141 86 Huddinge, Sweden.

Kjell Hultenby (K)

Department of Laboratory Medicine, Karolinska Institutet and Karolinska University Hospital, 141 57 Huddinge, Sweden.

Danica Gubrianska (D)

Experimental Cancer Medicine, Division of Biomolecular and Cellular Medicine (BCM), Department of Laboratory Medicine, Novum, Karolinska Institutet, 141 57 Huddinge, Sweden.
Clinical Research Center and Center for Allogeneic Stem Cell Transplantation, Karolinska University Hospital, 141 86 Huddinge, Sweden.

Ying Zhao (Y)

Experimental Cancer Medicine, Division of Biomolecular and Cellular Medicine (BCM), Department of Laboratory Medicine, Novum, Karolinska Institutet, 141 57 Huddinge, Sweden.
Clinical Research Center and Center for Allogeneic Stem Cell Transplantation, Karolinska University Hospital, 141 86 Huddinge, Sweden.

Manuchehr Abedi-Valugerdi (M)

Experimental Cancer Medicine, Division of Biomolecular and Cellular Medicine (BCM), Department of Laboratory Medicine, Novum, Karolinska Institutet, 141 57 Huddinge, Sweden.
Clinical Research Center and Center for Allogeneic Stem Cell Transplantation, Karolinska University Hospital, 141 86 Huddinge, Sweden.

Moustapha Hassan (M)

Experimental Cancer Medicine, Division of Biomolecular and Cellular Medicine (BCM), Department of Laboratory Medicine, Novum, Karolinska Institutet, 141 57 Huddinge, Sweden.
Clinical Research Center and Center for Allogeneic Stem Cell Transplantation, Karolinska University Hospital, 141 86 Huddinge, Sweden.

Classifications MeSH